PubRank

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

Clinical Trial ID NCT01697072

PubWeight™ 23.49‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01697072

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2014 1.26
2 Antibodies to watch in 2013: Mid-year update. MAbs 2013 1.13
3 Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 2014 1.02
4 Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014 1.00
5 Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015 0.97
6 Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014 0.97
7 Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 2014 0.92
8 HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014 0.92
9 c-Met as a Target for Personalized Therapy. Transl Oncogenomics 2015 0.92
10 The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther 2014 0.91
11 HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget 2014 0.91
12 Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015 0.86
13 Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016 0.86
14 Targeting hypoxic response for cancer therapy. Oncotarget 2016 0.85
15 How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist 2014 0.85
16 Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) 2015 0.85
17 Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol 2015 0.83
18 Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 2015 0.83
19 MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 2014 0.83
20 Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res 2015 0.81
21 Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes Cancer 2016 0.81
22 Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer. Clin Cancer Res 2015 0.81
23 From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract 2015 0.80
24 Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol 2014 0.79
25 Incomplete target neutralization by the anti-cancer antibody rilotumumab. MAbs 2016 0.78
26 Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors 2015 0.78
27 Novel therapy for advanced gastric cancer. World J Gastrointest Oncol 2015 0.75
Next 100